Achim Hoerauf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Achim Hoerauf has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Yaw Debrah
Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
9 shared publications Ohene Adjei
Kwame Nkrumah University of Science and Technology
6 shared publicationsSabine Mand
University of Bonn
6 shared publicationsSabine Specht
University of Bonn
6 shared publicationsYeboah Marfo-Debrekyei
Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR)
6 shared publications- Kenneth Pfarr
Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, University of Bonn, Bonn, Germany
5 shared publications
Latest Publications
- Open Access
- 6 December 2012
- Published by Springer Nature
Antibiotic targeting of wolbachia endosymbiotic bacteria as a new approach to the treatment of filarial (Onchocerca Volvulus) infection and disease
- 6 December 2012
- Published by Springer Nature
Open AccessAntibiotic targeting of wolbachia endosymbiotic bacteria as a new approach to the treatment of filarial (Onchocerca Volvulus) infection and disease
- Open Access
- 6 December 2012
- Published by Springer Nature
Antibiotic targeting of Wolbachia endosymbiotic bacteria as a new approach to the treatment of filarial (Wuchereria bancrofti) infection and disease
- 6 December 2012
- Published by Springer Nature
Open AccessAntibiotic targeting of Wolbachia endosymbiotic bacteria as a new approach to the treatment of filarial (Wuchereria bancrofti) infection and disease
- Open Access
- 1 January 2009
- Published by Springer Nature in Parasites & Vectors
- Vol. 2 (1) , 7
Onchocerciasis Control: Vision for the Future from a Ghanian perspective
Since 1987 onchocerciasis control has relied on the donation of ivermectin (Mectizan®, Merck & Co., Inc.) through the Mectizan Donation Programme. Recently, concern has been raised over the appearance of suboptimal responses to ivermectin in Ghana – highlighting the potential threat of the development of resistance to ivermectin. This report summarises a meeting held in Ghana to set the research agenda for future onchocerciasis control. The aim of this workshop was to define the research priorities for alternative drug and treatment regimes and control strategies to treat populations with existing evidence of suboptimal responsiveness and define research priorities for future control strategies in the event of the development of widespread ivermectin resistance.
- 1 January 2009
- Published by Springer Nature in Parasites & Vectors
- Vol. 2 (1) , 7
Open AccessOnchocerciasis Control: Vision for the Future from a Ghanian perspective
Since 1987 onchocerciasis control has relied on the donation of ivermectin (Mectizan®, Merck & Co., Inc.) through the Mectizan Donation Programme. Recently, concern has been raised over the appearance of suboptimal responses to ivermectin in Ghana – highlighting the potential threat of the development of resistance to ivermectin. This report summarises a meeting held in Ghana to set the research agenda for future onchocerciasis control. The aim of this workshop was to define the research priorities for alternative drug and treatment regimes and control strategies to treat populations with existing evidence of suboptimal responsiveness and define research priorities for future control strategies in the event of the development of widespread ivermectin resistance.
- 1 December 2008
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 21 (6) , 673-681
Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis
Chemotherapy against onchocerciasis and lymphatic filariasis has been discussed mainly within the framework of mass drug administration with diethylcarbamazine, ivermectin and albendazole. Although strong reductions in infection prevalence were achieved, the regimes for these drugs do not fully cover needs of individual patients who seek treatment because of symptoms. Chemotherapy against filarial Wolbachia endosymbionts with doxycycline showed higher antiparasitic efficacy in onchocerciasis and lymphatic filariasis and also improved disease. This review details the recent indications for this new treatment, focussing on regimes for individual drug administration. A regimen of 6-week/100 mg doxycycline per day sterilized adult female Onchocerca volvulus. Two hundred milligrams doxycycline per day for 4 or 6 weeks revealed 50 and 60% macrofilaricidal effects, respectively. Reduction of 80-90% of adult worms was observed in bancroftian filariasis with 200 mg/day doxycycline for 4 or 6 weeks. The latter regimen showed reduction of lymph vessel dilation and of hydrocele. Lymphoedema progression was halted and reversed in early stages. Different options for antiwolbachial individual drug administration are summarized here. With improving health systems in endemic countries, individuals will demand best-possible treatment and accelerate a shift from mass drug administration-only approaches to integrated approaches combining both mass drug administration and individual drug administration. Treatment may be further improved by new antibiotics detected in high-throughput settings.
- 1 December 2008
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 21 (6) , 673-681
Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis
Chemotherapy against onchocerciasis and lymphatic filariasis has been discussed mainly within the framework of mass drug administration with diethylcarbamazine, ivermectin and albendazole. Although strong reductions in infection prevalence were achieved, the regimes for these drugs do not fully cover needs of individual patients who seek treatment because of symptoms. Chemotherapy against filarial Wolbachia endosymbionts with doxycycline showed higher antiparasitic efficacy in onchocerciasis and lymphatic filariasis and also improved disease. This review details the recent indications for this new treatment, focussing on regimes for individual drug administration. A regimen of 6-week/100 mg doxycycline per day sterilized adult female Onchocerca volvulus. Two hundred milligrams doxycycline per day for 4 or 6 weeks revealed 50 and 60% macrofilaricidal effects, respectively. Reduction of 80-90% of adult worms was observed in bancroftian filariasis with 200 mg/day doxycycline for 4 or 6 weeks. The latter regimen showed reduction of lymph vessel dilation and of hydrocele. Lymphoedema progression was halted and reversed in early stages. Different options for antiwolbachial individual drug administration are summarized here. With improving health systems in endemic countries, individuals will demand best-possible treatment and accelerate a shift from mass drug administration-only approaches to integrated approaches combining both mass drug administration and individual drug administration. Treatment may be further improved by new antibiotics detected in high-throughput settings.
- Open Access
- 7 November 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (11) , 3101-3113
Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR‐L interaction, IL‐10 and TGF‐β
Regulatory T cells exert their function through the modulation of both T and B cell responses. Our previous studies demonstrated that IL‐10‐producing Treg (Tr1) can induce B cells to secrete IgG4 in a cell‐contact‐dependent manner. The benefit of such non‐inflammatory B‐cell responses is apparent in the hyporesponsive state of patients with helminth infections such as Onchocerciasis. Here, we investigated the mechanisms involved to induce IgG4, within B:Tr‐cell co‐cultures, using IL‐10‐producing tetanus‐toxoid‐specific regulatory T cell lines and clones (Tr‐TCC) from human PBMC. During the generation process, we found that increasing Foxp3 levels in regulatory T cell lines correlated with their ability to induce IgG4 in B cells. Using Tr‐TCC, we found that blocking glucocorticoid‐induced tumour necrosis factor receptor‐related protein (GITR) molecules selectively prevented IgG4 production as did neutralizing Ab to glucocorticoid‐induced tumour necrosis factor receptor‐related protein ligand (GITR‐L), IL‐10 and TGF‐β. Furthermore, the prevention of IgG4 induction by anti‐GITR Ab was reversed by excess rIL‐10 but not rTGF‐β. In contrast, anti‐ICOS and anti‐CTLA‐4 Abs had no effect. When compared with Tr‐TCC, freshly isolated CD4+CD25+ T cells, but not effector T cell populations, induced low levels of IgG4, which were also blocked by anti‐GITR and anti‐GITR‐L Ab. Thus, the mechanism of IgG4 induction by regulatory cells involves GITR–GITR‐L interactions, IL‐10 and TGF‐β.
- 7 November 2008
- Published by Wiley in European Journal of Immunology
- Vol. 38 (11) , 3101-3113
Open AccessTr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR‐L interaction, IL‐10 and TGF‐β
Regulatory T cells exert their function through the modulation of both T and B cell responses. Our previous studies demonstrated that IL‐10‐producing Treg (Tr1) can induce B cells to secrete IgG4 in a cell‐contact‐dependent manner. The benefit of such non‐inflammatory B‐cell responses is apparent in the hyporesponsive state of patients with helminth infections such as Onchocerciasis. Here, we investigated the mechanisms involved to induce IgG4, within B:Tr‐cell co‐cultures, using IL‐10‐producing tetanus‐toxoid‐specific regulatory T cell lines and clones (Tr‐TCC) from human PBMC. During the generation process, we found that increasing Foxp3 levels in regulatory T cell lines correlated with their ability to induce IgG4 in B cells. Using Tr‐TCC, we found that blocking glucocorticoid‐induced tumour necrosis factor receptor‐related protein (GITR) molecules selectively prevented IgG4 production as did neutralizing Ab to glucocorticoid‐induced tumour necrosis factor receptor‐related protein ligand (GITR‐L), IL‐10 and TGF‐β. Furthermore, the prevention of IgG4 induction by anti‐GITR Ab was reversed by excess rIL‐10 but not rTGF‐β. In contrast, anti‐ICOS and anti‐CTLA‐4 Abs had no effect. When compared with Tr‐TCC, freshly isolated CD4+CD25+ T cells, but not effector T cell populations, induced low levels of IgG4, which were also blocked by anti‐GITR and anti‐GITR‐L Ab. Thus, the mechanism of IgG4 induction by regulatory cells involves GITR–GITR‐L interactions, IL‐10 and TGF‐β.
- Open Access
- 11 October 2008
- Published by Springer Nature in Parasitology Research
- Vol. 104 (2) , 437-447
Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus
The effects of 5-week doxycycline treatment on the depletion of Wolbachia endobacteria from Onchocerca volvulus, on the interruption of embryogenesis and on microfilariae production, and with regard to macrofilaricidal activity were studied. In 2003, in an endemic area in Ghana, 22 onchocerciasis patients received 100 mg/day doxycycline for 5 weeks. Two years after the start of the study, 20 treated and ten untreated patients were nodulectomized and skin microfilariae were counted. The onchocercomas were examined by immunohistology for the presence of Wolbachia, embryogenesis, and vitality of adult filariae. The latter two parameters were further assessed by alternating logistic regression analysis, taking into account the dependency of worms and nodules in patients. Doxycycline resulted in depletion of Wolbachia and in complete interruption of embryogenesis in all worms that were assumed to have been present during treatment. In the treated patients, only 51% of the female worms were alive, compared to 84% in the untreated patients, indicating a moderate but distinct macrofilaricidal activity of doxycycline at this dose. It is concluded that, in areas with ongoing transmission, doxycycline cannot replace regular ivermectin mass treatment because new infections would require repeated rounds of doxycycline. However, doxycycline can be used for the treatment of individuals outside transmission areas, in foci where ivermectin resistance may occur, and in countries where onchocerciasis and loiasis are co-endemic.
- 11 October 2008
- Published by Springer Nature in Parasitology Research
- Vol. 104 (2) , 437-447
Open AccessEfficacy of 5-week doxycycline treatment on adult Onchocerca volvulus
The effects of 5-week doxycycline treatment on the depletion of Wolbachia endobacteria from Onchocerca volvulus, on the interruption of embryogenesis and on microfilariae production, and with regard to macrofilaricidal activity were studied. In 2003, in an endemic area in Ghana, 22 onchocerciasis patients received 100 mg/day doxycycline for 5 weeks. Two years after the start of the study, 20 treated and ten untreated patients were nodulectomized and skin microfilariae were counted. The onchocercomas were examined by immunohistology for the presence of Wolbachia, embryogenesis, and vitality of adult filariae. The latter two parameters were further assessed by alternating logistic regression analysis, taking into account the dependency of worms and nodules in patients. Doxycycline resulted in depletion of Wolbachia and in complete interruption of embryogenesis in all worms that were assumed to have been present during treatment. In the treated patients, only 51% of the female worms were alive, compared to 84% in the untreated patients, indicating a moderate but distinct macrofilaricidal activity of doxycycline at this dose. It is concluded that, in areas with ongoing transmission, doxycycline cannot replace regular ivermectin mass treatment because new infections would require repeated rounds of doxycycline. However, doxycycline can be used for the treatment of individuals outside transmission areas, in foci where ivermectin resistance may occur, and in countries where onchocerciasis and loiasis are co-endemic.
- 18 April 2008
- Published by Springer Nature in Parasitology Research
- Vol. 103 (2) , 279-286
Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus
The effects of azithromycin treatment on the presence of Wolbachia endobacteria and on the embryogenesis and microfilariae production of Onchocerca volvulus were studied. In 2002, in an endemic area in Ghana, 37 onchocerciasis patients were treated for 6 weeks with azithromycin: 23 patients received 250 mg every day, and 14 took 1,200 mg once a week. After 6 and/or 12 months, all palpable worm nodules were extirpated from 31 treated and nine additional untreated patients, and the presence of Wolbachia and embryogenesis were assessed by immunohistology. In nodules taken 6 months after treatment with either dose and 12 months after 1,200 mg/week, the Wolbachia loads of the worms were not different from those of untreated worms. However, 12 months after the 250-mg/day azithromycin regimen, significantly less female worms (65% compared to 92% untreated ones) presented many Wolbachia, although the reduction was less pronounced than observed in other studies after treatment with doxycycline. Embryogenesis and microfilariae production were not reduced. It is concluded that azithromycin administered alone for 6 weeks at 250 mg/day or 1,200 mg/week is not suitable for treatment of human onchocerciasis. But daily azithromycin should be studied in combination with other drugs and with other doses.
- 18 April 2008
- Published by Springer Nature in Parasitology Research
- Vol. 103 (2) , 279-286
Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus
The effects of azithromycin treatment on the presence of Wolbachia endobacteria and on the embryogenesis and microfilariae production of Onchocerca volvulus were studied. In 2002, in an endemic area in Ghana, 37 onchocerciasis patients were treated for 6 weeks with azithromycin: 23 patients received 250 mg every day, and 14 took 1,200 mg once a week. After 6 and/or 12 months, all palpable worm nodules were extirpated from 31 treated and nine additional untreated patients, and the presence of Wolbachia and embryogenesis were assessed by immunohistology. In nodules taken 6 months after treatment with either dose and 12 months after 1,200 mg/week, the Wolbachia loads of the worms were not different from those of untreated worms. However, 12 months after the 250-mg/day azithromycin regimen, significantly less female worms (65% compared to 92% untreated ones) presented many Wolbachia, although the reduction was less pronounced than observed in other studies after treatment with doxycycline. Embryogenesis and microfilariae production were not reduced. It is concluded that azithromycin administered alone for 6 weeks at 250 mg/day or 1,200 mg/week is not suitable for treatment of human onchocerciasis. But daily azithromycin should be studied in combination with other drugs and with other doses.
- Open Access
- 26 January 2008
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 197 (3) , 335
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
- 26 January 2008
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 197 (3) , 335
Open AccessWolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
- Open Access
- 13 November 2007
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 197 (3) , 295-311
Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
In a randomized, placebo-controlled trial in Ghana, 67 onchocerciasis patients received 200-mg/day doxycycline for 4–6 weeks, followed by ivermectin (IVM) after 6 months. After 6–27 months, efficacy was evaluated by onchocercoma histology, PCR and microfilariae determination. Administration of doxycycline resulted in endobacteria depletion and female worm sterilization. The 6-week treatment was macrofilaricidal, with >60% of the female worms found dead, despite the presence of new, Wolbachia-containing worms acquired after the administration of doxycycline. Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.
- 13 November 2007
- Published by Springer Nature in Medical Microbiology and Immunology
- Vol. 197 (3) , 295-311
Open AccessWolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study
In a randomized, placebo-controlled trial in Ghana, 67 onchocerciasis patients received 200-mg/day doxycycline for 4–6 weeks, followed by ivermectin (IVM) after 6 months. After 6–27 months, efficacy was evaluated by onchocercoma histology, PCR and microfilariae determination. Administration of doxycycline resulted in endobacteria depletion and female worm sterilization. The 6-week treatment was macrofilaricidal, with >60% of the female worms found dead, despite the presence of new, Wolbachia-containing worms acquired after the administration of doxycycline. Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.